{"entity":{"id":"fmc-220","kind":"drug","name":"FMC-220","aka":[],"tldr":"FMC-220 is an experimental covalent small molecule from Frontier Medicines, at a stage the company does not state for tumours with the TP53 Y220C mutation.","summary":"FMC-220 is a covalent small molecule from Frontier Medicines. A covalent activator of the p53 Y220C mutant protein, designed to restore p53 tumour-suppressor function selectively. The company does not state its stage; it is aimed at tumours with the TP53 Y220C mutation. No clinical trial naming it is registered on ClinicalTrials.gov. No registered trial on ClinicalTrials.gov; the page gives no stage. It has not been shown to work in people.","asOf":"2026-11-03","links":[{"label":"Frontier Medicines: frontiermeds.com","url":"https://www.frontiermeds.com/precision-pipeline/fmc-220-p53-y220c-activator"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["tp53"],"drugs":[],"companies":["frontier-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"FMC-220","modality":"Covalent small molecule","mechanism":"A covalent activator of the p53 Y220C mutant protein, designed to restore p53 tumour-suppressor function selectively.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/fmc-220/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"}],"company":[{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/"}]}}